SEP 24, 2014 08:00 AM PDT

Role of Academic Institutions in Target Selection

  • Director, Tri-I TDI
      Michael Foley is the Director of the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), a newly formed partnership between Memorial Sloan Kettering , The Rockefeller University and Weill Cornell Medical College, to speed drug discovery. Foley brings 25 years of industry and academic experience to Tri-I TDI, helping to launch four companies and one academic institute and placing 12 drugs into clinical development. He was most recently the Director of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. Michael was a co-founder of Infinity Pharmaceuticals and served as VP Chemistry from 2001 to 2006. He was also a co-founder of CombinatoRx and Forma Therapeutics, as well as working at Bristol-Myers Squibb and GlaxoSmithKline. He obtained his Ph.D. at Harvard, and helped establish the Harvard Institute of Chemistry and Cell Biology. In 2006, Michael joined the Broad Institute and served as director of the Therapeutics Platform. Foley received his B.S. in chemistry from St. Norbert College and his Ph.D. in chemistry from Harvard University.

    Target selection is arguably the most important decision in all drug discovery and development activities. No amount of great science can overcome the selection of the wrong target. The rapid expansion of potential targets for drug discovery as a result of modern genetic sequencing and analysis technologies has made target selection more challenging than ever before. This presentation will address the role of academic research centers in addressing the target selection problem

    Show Resources
    Loading Comments...